Durvalumab-话题@MedSci

#Durvalumab#

3篇内容 | 1899人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2232139, encodeId=5c3422321396f, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=ba5c1e796cf' target=_blank style='color:#2F92EE;'>#Tremelimumab#</a> <a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>, objectTitle=Nature：双重免疫检查点抑制加化疗对携带KEAP1/STK11突变的转移性非鳞状NSCLC患者有益, objectType=article, longId=847791, objectId=106b84e7913c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/bioon-com/202401020/1729377786046_2185383.png, objectUrl=/article/show_article.do?id=106b84e7913c, replyNumber=0, likeNumber=7, createdTime=2024-10-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=0, avatar=, status=0, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=null, followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2228349, encodeId=af962228349f3, content=<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a> <a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>, objectTitle=NEJM：小细胞肺癌治疗获新进展，Durvalumab作为辅助疗法显著延长局限期小细胞肺癌的总生存期与无进展生存期, objectType=article, longId=845124, objectId=098584512426, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719533984094_5579292.png, objectUrl=/article/show_article.do?id=098584512426, replyNumber=0, likeNumber=74, createdTime=2024-09-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=098584512426, moduleTitle=NEJM：小细胞肺癌治疗获新进展，Durvalumab作为辅助疗法显著延长局限期小细胞肺癌的总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=098584512426)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2227928, encodeId=ef6e222e9282b, content=<a href='/topic/show?id=843a85e9421' target=_blank style='color:#2F92EE;'>#膀胱癌#</a> <a href='/topic/show?id=b4975869e17' target=_blank style='color:#2F92EE;'>#新辅助化疗#</a> <a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>, objectTitle=NEJM：新疗法，终于提高了这类高度恶性膀胱癌的生存率！, objectType=article, longId=844857, objectId=eebd84485e80, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240623/1719153395387_5579292.png, objectUrl=/article/show_article.do?id=eebd84485e80, replyNumber=0, likeNumber=44, createdTime=2024-09-26, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=eebd84485e80, moduleTitle=NEJM：新疗法，终于提高了这类高度恶性膀胱癌的生存率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eebd84485e80)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2092790, encodeId=6e7e2092e9092, content=<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>联合EP成为广泛期SCLC<a href='/topic/show?id=5e2e4e08988' target=_blank style='color:#2F92EE;'>#小细胞肺癌#</a>, objectTitle=Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择, objectType=article, longId=180960, objectId=63fa180960d4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201910/20191011131042209.jpg, objectUrl=/article/show_article.do?id=63fa180960d4, replyNumber=0, likeNumber=106, createdTime=2022-10-10, rootId=0, userName=lifestar, userId=aa0e14, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63fa180960d4, moduleTitle=Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63fa180960d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1052879, encodeId=3aa110528e9b9, content=<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>研究表明，PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗具有改善无复发生存期的临床获益，并且跟PD-L1水平有一定相关。, objectTitle=Durvalumab, objectType=topic, longId=6338, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=134, createdTime=2021-09-18, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJlfgys76DEiaNtbYo2re3ibjrUPTRibEXRyFwAB4aAGiave842S0FQDf0wAoaH226NiaSoPPDzhndsf1g/132, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=919023, encodeId=d87191902315, content=<a href='/topic/show?id=a22d1e57696' target=_blank style='color:#2F92EE;'>#TNBC#</a>患者<a href='/topic/show?id=4012e904074' target=_blank style='color:#2F92EE;'>#维持治疗#</a>中<a href='/topic/show?id=a9ba633888' target=_blank style='color:#2F92EE;'>#Durvalumab#</a>的单药，在激素受体阳性和Her2阴性的患者中，维持化疗比durvalumab更有效。这需要进一步研究！, objectTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, objectType=article, longId=206034, objectId=c40a2060347b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2021121/1611240656694_2467676.PNG, objectUrl=/article/show_article.do?id=c40a2060347b, replyNumber=0, likeNumber=258, createdTime=2021-01-22, rootId=0, userName=lifefamily, userId=a33789389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c40a2060347b, moduleTitle=Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c40a2060347b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Durvalumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #Tremelimumab# #Durvalumab#

2024-10-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#小细胞肺癌# #Durvalumab#

NEJM：小细胞肺癌治疗获新进展，Durvalumab作为辅助疗法显著延长局限期小细胞肺癌的总生存期与无进展生存期

2024-09-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#膀胱癌# #新辅助化疗# #Durvalumab#

NEJM：新疗法，终于提高了这类高度恶性膀胱癌的生存率！

2024-09-26发表于上海

lifestar (审核中...)

前往app查看评论内容

#Durvalumab#联合EP成为广泛期SCLC#小细胞肺癌#

Durvalumab联合EP成为广泛期SCLC小细胞肺癌一线治疗新选择

2022-10-10

yangchou (审核中...)

前往app查看评论内容

#Durvalumab#研究表明，PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗具有改善无复发生存期的临床获益，并且跟PD-L1水平有一定相关。

2021-09-18

lifefamily (审核中...)

前往app查看评论内容

#TNBC#患者#维持治疗#中#Durvalumab#的单药，在激素受体阳性和Her2阴性的患者中，维持化疗比durvalumab更有效。这需要进一步研究！

Nat Med：转移性乳腺癌中Durvalumab与维持化疗的疗效比较

2021-01-22

科室
- - 订阅+
  - 更多科室
工具
服务